2 ms·
Do you mean the NSF and NIH? Certainly, fund them with what currently goes to pharma for executives, shareholders, lobbying, and marketing. Fund meaningful work
by toomuchtodo 3y ago
Do you mean the NSF and NIH? Certainly, fund them with what currently goes to pharma for executives, shareholders, lobbying, and marketing. Fund meaningful work, not gravy for corporate performance artists (Part D is funded by general revenues, beneficiary premiums, and state contributions).
Cut out the middleman.
"In 2021, Medicare Part D covered more than 3,500 prescription drug products, with total gross spending of $216 billion, not accounting for rebates paid by drug manufacturers to pharmacy benefit managers (PBMs)."
https://www.kff.org/medicare/issue-brief/a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending/ https://www.kff.org/medicare/issue-brief/a-small-number-of-d...
From this post:
> Peter Maybarduk, the director of the Access to Medicines program at Public Citizen, a watchdog organization, who also testified at the hearing, hit back at the main pharmaceutical talking points along with Sanders. That included noting that the makers of the 10 drugs selected for the first round of Medicare price negotiation spent $10 billion more on self-enriching activities than R&D.
($200B/year buys a lot of manufacturing, distribution, admin, and whatever is left over for amortized and ongoing R&D)
- pompino 3y ago>Fund meaningful work, not gravy for corporate performance artists (Part D is funded by general revenues, beneficiary premiums, and state contributions). The problem is that nobody actually knows or can predict what "meaningful work" is because drug discovery is a graveyard with a >90% death rate.